新规格阿仑膦酸钠治疗老年骨质疏松症30例

目的观察新规格阿仑膦酸钠治疗老年骨质疏松的疗效及安全性。方法老年骨质疏松病人61例,随机分为2组,治疗组男性10例,女性20例,年龄(78±s 4)a,每周口服阿仑膦酸钠1片(70 mg),同时口服骨化三醇0.25μg·d~(-1);对照组男性11例,女性20例,年龄(77±6)a,仅服骨化三醇,疗程均为6 mo。观察2组骨骼疼痛情况及骨密度变化。结果治疗后,治疗组骨骼疼痛改善有效率87% (26/30),对照组65%(20/31),2组比较差异显著(P<0.05)。治疗组除华氏三角区外各部位骨密度均较治疗前上升,提高骨密度的有效率达73%(22/30),对照组为45%(14/31),2组间比较,差异有显著意义(P<0.05)。治疗前后2组三大常规,肝、肾功能等均无明显改变,无明显不良反应。结论新规格阿仑膦酸钠治疗老年骨质疏松安全、有效。

Analysis of new specification alendronate in treating senile osteoporosis

AIM To evaluate the clinical therapeutic effect and safety of new specification alendronate for senile osteoporosis.METHODS Sixty-one senile osteoporotic patients were randomly divided into two groups,30 patients (M 10,F 20,age(78±s 4) a) in the treatment group and 31 patients(M 11,F 20, age(77±6)a) in the control group.The patients in the treatment group were treated with alendronate 70 mg·wk~(-1) and calcitriol 0.25μg·d~(-1),whilethe patients in the control group with calcitriol 0.25μg·d~(-1) only,both for 6 mo as a course.The changes of bone pain and bone mineral density(BMD)were closely observed. RESULTS After the therapy,pain alleviated efficacies of treatment group and control group were 87%(26/ 30)and 65%(20/31),with significant difference(P<0.05).The BMD of the treatment group increased except that in Ward's angle area,to the average efficiency BMD of 73%(22/30),however,the control group increased the average efficient BMD of 45%(14/31),showing significant difference between the two groups(P<0.05).Biochemical levels of the three main routines,hepatic and renal functions of the two groups revealed no perceivable change.CONCLUSION Alendronate is effective and safe for treatment of senile osteoporosis.